news aktuell GmbHnews aktuell GmbH

DocMorris goes European: new branding for marketplaces in Spain and France

Del

Heerlen/Barcelona, 11.02.2021 – DocMorris is taking the next step in implementing its new brand architecture on the way to becoming the European umbrella brand of the digital healthcare ecosystem of the Zur Rose Group. The successful launch of the new branding for the DocMorris pharmacy and the DocMorris+ healthcare platform in Germany marked just the beginning of a shift of paradigm to digital healthcare. This successful first step in Germany is now followed by PromoFarma, the leading brand for online pharmacy marketplaces in Spain, and DoctiPharma, the second biggest brand in France, who see their brand now linked to the DocMorris brand identity.

The new brand appearance of PromoFarma and DoctiPharma underlines its brand evolutions by using the green heart as a symbol for health. The varying shades of green for the heart represent the variety of current and future health solutions, which can be made even more personal and individual thanks to digitalisation. The light green “by DocMorris” descriptor confirms its link and shows both marketplaces are part of the European healthcare ecosystem.

DocMorris, best known in Germany, has been chosen by the Zur Rose Group as umbrella brand for its European healthcare ecosystem. The international success of the Christmas film “#Herzensangelegenheit” [a matter of the heart] emphasises the strength of the DocMorris brand and how the brand emotionally resonates with consumers across European markets. The cooperation with global healthcare company Novo Nordisk in Germany – with the intention to expand it across Europe – demonstrates how important it is to work with top-class partners in healthcare to bring the ecosystem to life under one single brand. Combining specialist knowledge from partners with consumer reach makes it possible to better enable people to manage their own health and improve their quality of life conveniently and flexibly. Gaining additional marketplace expertise in Spain and France within the healthcare ecosystem increases its attractiveness for consumers allowing for more product accessibility and faster time-to-market. With the ambition to expand further their product offering and providing additional digital services, PromoFarma and DoctiPharma will also benefit from the existing expertise under the DocMorris brand and many years of experience across the Zur Rose Group to make it even simpler for people to access healthcare.

On this basis, the DocMorris healthcare ecosystem will enable people all over Europe to manage their health in one click – safely and easily. The healthcare ecosystem will make it possible for all users, medical specialists, pharmacists and healthcare service providers to experience the vision of seamless and personal 360-degree health journeys.

The European DocMorris branding was developed with the famous international design agency Mucho of Barcelona, Spain.

Kontakter

eHealth ecosystem contact
Betül Susamis Unaran
Chief Strategy and Digital Officer
Email: betul.unaran@zurrose.com
Phone +41 79 834 41 40

Om news aktuell GmbH

news aktuell GmbH
news aktuell GmbH
Mittelweg 144
20148 Hamburg

+49 (0)40 4113-32589http://www.newsaktuell.de

news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.

Følg pressemeldinger fra news aktuell GmbH

Registrer deg med din e-postadresse under for å få de nyeste sakene fra news aktuell GmbH på e-post fortløpende. Du kan melde deg av når som helst.

Siste pressemeldinger fra news aktuell GmbH

Vyoma’s first Space Domain Awareness satellite has reached orbit13.1.2026 13:42:00 CET | Press release

Munich, 13. January 2026 - Vyoma, a Germany-based company providing Space Domain Awareness (SDA) capabilities, has launched its pioneering surveillance satellite, Flamingo-1, on Sunday, January 11th, 2026 from Vandenberg Space Force Base, California, USA. It was launched aboard the Twilight rideshare mission with SpaceX via Germany-based launch integrator Exolaunch. The satellite was deployed to its operational Sun-synchronous orbit of approximately 500-km in altitude. This marks a significant achievement for the company, which patented the operational concept of an optimized SDA mission. Flamingo-1, equipped with an optical sensor for space-based space surveillance, is a gamechanger for Europe, strengthening SDA efforts directly from orbit. The advanced optical instrument will detect, track and characterize space objects, such as debris and other satellites. Crucially, it will allow Vyoma and its customers to follow up on manoeuvring objects and derive insights into adversary actions

Acousia Announces Completion of Patient Enrollment in Phase 2 PROHEAR Study Evaluating ACOU085 (INN: Bimokalner) for the Prevention of Cisplatin-Induced Ototoxicity8.1.2026 09:00:00 CET | Press release

Tübingen, Germany, January 8, 2026 Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced the completion of patient enrollment in its Phase 2 PROHEAR clinical study. ACOU085 (INN: Bimokalner) is a proprietary, first-in-class small molecule that has demonstrated robust and reproducible efficacy across multiple preclinical hearing loss models, including drug-induced ototoxicity. The PROHEAR Study is a double-blind, randomized, placebo-controlled, split-body, multicenter Phase 2 trial. It enrolled young male patients with metastatic testicular cancer who are scheduled to receive cisplatin-based chemotherapy. While cisplatin is a highly effective chemotherapeutic agent, cumulative doses of ≥300 mg/m² lead to clinically meaningful, permanent hearing loss in the majority of patients. Fifteen leading university hospitals in Germany are participating in this interdisciplinary study. Patients are randomized

I vårt presserom finner du alle våre siste pressemeldinger, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye